Trial Profile

A Phase I clinical study to test safety and efficacy of prophylactic vaccine AVX70120 for yellow fever

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immunostimulants (Primary)
Indications Yellow fever
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms SAFYR

Most Recent Events

01 Jul 2024 New trial record
24 Jun 2024 According to an AstriVax media release, first participants have been dosed in this SAFYR clinical trial. This trial will be conducted in two Belgium-based, clinical trial sites: the Centre for Vaccinology in Ghent and Vaccinopolis in Antwerp.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com